Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Universite Paris-Saclay, Assistance Publique-HôPitaux De Paris (Aphp)
InventorsChristophe GUIGNABERT, Laurent SAVALE, Ly ieng TU, Marc HUMBERT, Athénaïs BOUCLY, Olivier SITBON
Estimating the term…
In the present invention, in Pulmonary Arterial Hypertension (PAH) patient's blood samples (EFFORT cohort), inventors results indicate that activin-Smad2/3 signaling is overactive, as reflected by the overabundance of inhibin-βA, inhibin-βB, activin type-I and type-II receptors, and phospho-Smad2/3 in PAH vascular endothelial and smooth muscle cells and by the fact that elevated levels of activin A and follistatin-like 3 (FSTL3) level in serum predict adverse outcome. With an independent external PAH cohort, inventors confirmed that both activin A and FSTL3 are prognostic biomarkers in PAH. Thereafter, this approach allows to identify a BMP/TGF ligands combinations that represent a reliable biomarker of PAH severity and/or mortality, validated in a second independent cohorts of PAH patient (Imperial College of London, UK study) 2-biomarker panel composed of activin A and follistatin-like 3 (FSTL3) that was independently associated with prognosis both at the time of PAH diagnosis and at the first follow-up after PAH therapy initiation. More specifically present invention relates to methods for prognosis and/or monitoring of the severe form of Pulmonary Hypertension (PH) and PAH through comparison of specific markers combinations in PH or PAH patient.
An in vitro method for assessing a subject's risk of having or developing a severe form of Pulmonary Hypertension (PH) and then treating the subject, comprising
An in-vitro method for assessing a Pulmonary Hypertension (PH) patient's risk of having a poor prognostic of survival and then treating the patient, comprising
An in vitro method for monitoring Pulmonary Hypertension (PH) disease in a subject in need thereof and then treating the subject comprising
An in vitro method for monitoring a treatment of Pulmonary Hypertension (PH) in a subject comprising the steps of
(canceled)
A method of treating Pulmonary Hypertension (PH) in a subject comprising the steps of:
Dependencies are inferred from the claim text.